

MARRONE BIO INNOVATIONS INC  
Form NT 10-Q  
May 18, 2015

SEC FILE NUMBER

001-36030

CUSIP NUMBER

57165B106

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 12b-25**

**NOTIFICATION OF LATE FILING**

(Check one):     Form 10-K     Form 20-F     Form 11-K     Form 10-Q  
                   Form 10-D     Form N-SAR     Form N-CSR

For Period Ended: March 31, 2015

- Transition Report on Form 10-K
- Transition Report on Form 20-F
- Transition Report on Form 11-K
- Transition Report on Form 10-Q
- Transition Report on Form N-SAR

For the Transition Period Ended:

*Read Instruction (on back page) Before Preparing Form. Please Print or Type.*

**Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.**

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

**PART I REGISTRANT INFORMATION**

**Marrone Bio Innovations, Inc.**

**Full Name of Registrant**

**Former Name if Applicable**

**1540 Drew Avenue**

**Address of Principal Executive Office (*Street and Number*)**

**Davis, California 95618**

**City, State and Zip Code**

## PART II RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

- (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
- (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
- (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

## PART III NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period. (Attach extra Sheets if Needed)

As previously reported, the Audit Committee (the Committee) of Marrone Bio Innovations, Inc. (the Company) in September 2014 commenced an internal investigation regarding certain accounting matters, and announced that it had concluded, after consultation with management, that the Company's previously reported financial statements as of December 31, 2013 and for the fiscal year ended December 31, 2013, the related report of the independent auditors on those 2013 financial statements dated March 25, 2014, and the unaudited interim financial statements as of and for the three months and the three and six months ended March 31, 2014 and June 30, 2014, respectively, should no longer be relied upon. Following the February 2015 completion of the internal investigation, in April 2015, the Company announced that the Committee concluded, after consultation with management, that in addition to the foregoing, the Company's previously reported unaudited interim financial statements as of and for the three months, the three and six months and the three and nine months ended March 31, 2013, June 30, 2013 and September 30, 2013, respectively, also should no longer be relied upon (all such statements together, the Reported Financial Statements).

Management of the Company has been evaluating the necessity, nature and scope of any restatements to any of its previously filed financial statements based on the findings and conclusions of the Committee's internal investigation. Principally, the Committee determined that as a result of the failure of certain employees to share with the Company's finance department or the external auditors important transaction terms with distributors, including inventory protection arrangements that would permit the distributors to return to the Company certain unsold products, the Company inappropriately recognized revenue for certain historical sales transactions with these distributors prior to satisfying the criteria for revenue recognition required under U.S. Generally Accepted Accounting Principles (GAAP).

Accordingly, the Company's management has been evaluating all distributor sales transactions during the periods referenced above on a customer-by-customer and transaction-by-transaction basis, including relevant documents and seeking any details of any other undocumented arrangements or commitments. With respect to each individual transaction, the Company's management is evaluating relevant facts and circumstances to apply its revenue recognition policy. With respect to many transactions, to permit the Company to determine both (i) the appropriate methodology for accounting for those transactions and (ii) the appropriate timing and quantification of any product revenues arising from those transactions, the Company has sought to obtain additional information from certain of its distributors including information regarding the distributors' sales to end users of the products the Company shipped to the distributor.

In light of the nature and complexity of this ongoing process, while the Company anticipates that it will restate the Reported Financial Statements, the Company has not yet made any definitive conclusions regarding the nature, scope and specific financial impacts of such restatements, and cannot at this time provide an estimate of extent or effect of such restatements. Until the evaluation is finished, the Company is not able to complete and file the financial statements to be included in its Quarterly Report on Form 10-Q for the three months ended March 31, 2015 (the

Form 10-Q ) by the due date of May 15, 2015 or to announce financial results in a manner required by GAAP for any fiscal period as to which the Company has not yet provided financial results (the Unreported Periods ).

In addition, because the evaluation is not yet complete, and because the Company seeks the cooperation of third parties in connection with the evaluation, the Company cannot currently provide an estimate when the filing of the Form 10-Q, any announcements of financial results for the other Unreported Periods or any announcements regarding required restatements of the Reported Financial Statements will be made.

### **Forward Looking Statements**

Portions of this filing may constitute forward-looking statements and assumptions underlying such forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 (the PSLRA ), Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any such forward-looking statements are made within the safe-harbor protections of the PSLRA, should not be relied upon as representing our views as of any subsequent date, and we are under no obligation to, and expressly disclaims any responsibility to, update or alter these forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements in this release include those regarding the Company's financial statements and expectations regarding the extent or effect of any restatements and the timing of the announcement of financial results or any restatements. Such forward-looking statements are based on information available to the Company as of the date of this release and involve a number of risks and uncertainties, some beyond its control, that could cause actual results to differ materially from those anticipated by these forward-looking statements. Such risks include uncertainty surrounding management's evaluation of the nature and scope of any necessary restatements to its previously filed financial statements, the types of errors and adjustments that may be required in any such restatement, cooperation of the Company's third party distributors, potential legal or regulatory action related to the matters under investigation, and adverse decisions by the SEC or NASDAQ. Additional information that could lead to material changes in the Company's performance is contained in its filings with the SEC.

## **PART IV OTHER INFORMATION**

(1) Name and telephone number of person to contact in regard to this notification

**James Boyd**  
(Name)

**(530)**  
(Area Code)

**750-2800**  
(Telephone Number)

- (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).     Yes     No

Quarterly Report on Form 10-Q for the quarter ended September 30, 2014

Annual Report on Form 10-K for the fiscal year ended December 31, 2014

- (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?     Yes     No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

The Company is unable to provide a reasonable estimate of the changes in the results of operations for the three months ended March 31, 2015 and 2014 because, as indicated above in Part III of this Form 12b-25, which is incorporated by reference into this Part IV(3), the Company is unable to complete the preparation and review of all necessary information and disclosures for the three months ended March 31, 2015 and 2014.

**Marrone Bio Innovations, Inc.**

**(Name of Registrant as Specified in Charter)**

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date **May 18, 2015**

By **/s/ James B. Boyd**  
**James B. Boyd**  
**Chief Financial Officer**